Analytical Development Laboratory, Intas Pharmaceuticals Ltd. (Biopharma Division), Ahmedabad, Gujarat, India.
Biocharacterization Development Laboratory, Intas Pharmaceuticals Ltd. (Biopharma Division), Ahmedabad, Gujarat, India.
PLoS One. 2019 Mar 13;14(3):e0212622. doi: 10.1371/journal.pone.0212622. eCollection 2019.
The approval of biosimilars requires demonstration of biosimilarity, which rests on the base of thorough analytical characterization of the biosimilar product. In addition to demonstration of biosimilarity, the product related impurities need to be thoroughly characterized and controlled at minimal levels. Pegylation of peptides and proteins creates significant challenges for detailed structural characterization, such as PEG (Poly Ethylene Glycol) heterogeneity, site of addition and number of attached pegylated moieties. A combination of several methods including circular dichroism, FTIR (Fourier-transform Infrared Spectroscopy), fluorescence spectroscopy, DSC (Differential Scanning Calorimetry), 1D and 2D NMR (Nuclear Magnetic Resonance), Edman degradation and peptide mapping by LC-MS (Liquid Chromatography Mass Spectrometry) were used for characterization of N-terminally pegylated filgrastim. Product related impurities such as oxidized, reduced, deamidated, dipegylated variants and monopegylated positional isomers have been characterized in detail using various HPLC (High Performance Liquid Chromatography) based methods and LC-MS techniques. The functional characterization in terms of receptor binding and cell proliferation assay was conducted for the similarity assessment and the potential impact of the product variants on the in vitro biological activity has also been assessed. In summary, this study presents, for the first time, a detailed structural and molecular level characterization of a biosimilar pegfilgrastim providing a strong base for the demonstration of overall biosimilarity of the product with the innovator product.
生物类似药的批准需要证明其生物相似性,这基于对生物类似药产品的全面分析特性鉴定。除了证明生物相似性外,还需要对产品相关杂质进行彻底的特征描述,并将其控制在最低水平。肽和蛋白质的聚乙二醇化会给详细的结构特征鉴定带来巨大的挑战,例如聚乙二醇(PEG)的不均一性、加成部位和连接的聚乙二醇化部分的数量。几种方法的结合,包括圆二色性、傅里叶变换红外光谱(FTIR)、荧光光谱、差示扫描量热法(DSC)、一维和二维核磁共振(NMR)、Edman 降解和通过 LC-MS 的肽图分析,被用于鉴定 N 端聚乙二醇化的非格司亭。使用各种基于高效液相色谱(HPLC)的方法和 LC-MS 技术,对产品相关杂质(如氧化、还原、脱酰胺、二聚化变体和单聚化位置异构体)进行了详细的特征描述。进行了受体结合和细胞增殖测定的功能特征描述,以进行相似性评估,并评估了产品变体对体外生物活性的潜在影响。总之,本研究首次对一种生物类似药聚乙二醇化非格司亭进行了详细的结构和分子水平的特征描述,为该产品与原研产品的整体生物相似性提供了有力的依据。